Characterization of blood bank and transfusion medicine practices for pregnant individuals with fetuses at risk of hemolytic disease in the United States.

Jeremy W Jacobs Garrett S Booth Kenneth Jpseph Moise Brian David Adkins Sara Bakhtary Ross M Fasano Ruchika GoelHannah D HintonSadia A LaghariLaura Dilly Stephens Christopher A Tormey Elizabeth P Crowe Evan M Bloch Elizabeth A Abels

Published in: Transfusion (2024)

There is heterogeneity across US institutions regarding the testing, monitoring, and reporting practices for pregnant individuals with fetuses at risk of HDFN, including the use of antibody titers in screening and monitoring programs, the use of paternal RBC antigen testing and cffDNA, and documentation of fetal antigen results. Standardization of laboratory testing protocols and closer collaboration between the blood bank and transfusion medicine service and the obstetric/maternal-fetal medicine service are needed.

Keyphrases

healthcare
pregnant women
mental health
primary care
cardiac surgery
gestational age
public health
birth weight
sickle cell disease
single cell
emergency department
electronic health record
pregnancy outcomes
adverse drug
physical activity
red blood cell